Evidence map›Paper›PMID 32817435›Full record

ReviewProceedings of the National Academy of Sciences of the United States of America2020

Opportunities and limitations of genetically modified nonhuman primate models for neuroscience research.

Guoping Feng, Frances E Jensen, Henry T Greely, Hideyuki Okano, Stefan Treue, Angela C Roberts, James G Fox, Sarah Caddick, Mu-Ming Poo, William T Newsome and 1 more

Abstract readReview
In one paragraph

Review in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Longitudinal Characterization of GiantResearch (Washington, D.C.) · 2026
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Guoping FengDepartment of Brain and Cognitive Sciences, McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA 02139; fengg@mit.edu frances.jensen@pennmedicine.upenn.edu bnewsome@stanford.edu jhmorrison@ucdavis.edu.ORCID 0000-0002-8021-277X
Frances E JensenDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104; fengg@mit.edu frances.jensen@pennmedicine.upenn.edu bnewsome@stanford.edu jhmorrison@ucdavis.edu.
Henry T GreelyCenter for Law and the Biosciences, Stanford University, Stanford, CA 94305.ORCID 0000-0002-1105-6734
Hideyuki OkanoDepartment of Physiology, Keio University School of Medicine, Shinjukuku, 160-8592 Tokyo, Japan.ORCID 0000-0001-7482-5935
Stefan TreueCognitive Neuroscience Laboratory, German Primate Center-Leibniz Institute for Primate Research, 37077 Goettingen, Germany.
Angela C RobertsDepartment of Physiology, Development, and Neuroscience, University of Cambridge, CB2 3DY Cambridge, United Kingdom.ORCID 0000-0003-2873-157X
James G FoxDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA 02139.
Sarah CaddickThe Gatsby Charitable Foundation, SW1V 1AP London, United Kingdom.ORCID 0000-0001-8823-8838
Mu-Ming PooInstitute of Neuroscience, State Key Laboratory of Neuroscience, Chinese Academy of Sciences Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, 200031 Shanghai, China.
William T NewsomeWu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA 94305; fengg@mit.edu frances.jensen@pennmedicine.upenn.edu bnewsome@stanford.edu jhmorrison@ucdavis.edu.ORCID 0000-0002-4370-5022
John H MorrisonCalifornia National Primate Research Center, University of California, Davis, CA 95616; fengg@mit.edu frances.jensen@pennmedicine.upenn.edu bnewsome@stanford.edu jhmorrison@ucdavis.edu.ORCID 0000-0002-9584-4411

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Res Support CoreP50MH094271 · NIMH · HARVARD UNIVERSITY · PI HENSCH, TAKAO K · 2011 to 2022
$18.6M
A Molecular and Cellular Atlas of the Marmoset BrainU01MH114819 · NIMH · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI FENG, GUOPING · 2017 to 2021
$6.9M
Investigating the Role of T cells in Age-related Neurodegeneration in HIV InfectionRF1AG061001 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI IYER, SWAMINATHAN SMITA, MORRISON, JOHN H · 2018 to 2022
$5.0M
Knockin marmoset reporters for non-invasive measuring of genome-editing efficiencyU24OD026638 · OD · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI FENG, GUOPING · 2018 to 2022
$4.0M
A Nonhuman Primate Model of Early Alzheimer's Disease PathogenesisRF1AG063837 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BAXTER, MARK G, BLISS-MOREAU, ELIZA · 2019 to 2019
$3.8M
Interaction between epilepsy and AD: novel therapeutic strategiesR21NS105437 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI JENSEN, FRANCES E · 2018 to 2019
$443k
Quantifying synaptic density loss in a monkey model of early Alzheimer's DiseaseR21AG064448 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHAUDHARI, ABHIJIT J, MORRISON, JOHN H · 2019 to 2020
$425k
NIA NIH HHS R21 AG064448NIA NIH HHS RF1 AG061001NIA NIH HHS RF1 AG063837NIH HHS P51 OD011107NIH HHS U24 OD026638NIMH NIH HHS P50 MH094271NIMH NIH HHS U01 MH114819NINDS NIH HHS R21 NS105437
6 · The paper itself

Abstract

The recently developed new genome-editing technologies, such as the CRISPR/Cas system, have opened the door for generating genetically modified nonhuman primate (NHP) models for basic neuroscience and brain disorders research. The complex circuit formation and experience-dependent refinement of the human brain are very difficult to model in vitro, and thus require use of in vivo whole-animal models. For many neurodevelopmental and psychiatric disorders, abnormal circuit formation and refinement might be at the center of their pathophysiology. Importantly, many of the critical circuits and regional cell populations implicated in higher human cognitive function and in many psychiatric disorders are not present in lower mammalian brains, while these analogous areas are replicated in NHP brains. Indeed, neuropsychiatric disorders represent a tremendous health and economic burden globally. The emerging field of genetically modified NHP models has the potential to transform our study of higher brain function and dramatically facilitate the development of effective treatment for human brain disorders. In this paper, we discuss the importance of developing such models, the infrastructure and training needed to maximize the impact of such models, and ethical standards required for using these models.

Indexed as

Disease Models, AnimalAnimal ExperimentationAnimalsMental DisordersNervous System DiseasesNeurosciencesPrimatesCRISPRdisease modelsgenetic engineeringnonhuman primateprimates

Identifiers

PMID32817435
PMCPMC7533691

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.